EP2585055A1 - Utilisation de stimulateurs et d'activateurs de la guanylate-cyclase soluble pour le traitement de la drépanocytose et la conservation de substituts sanguins - Google Patents

Utilisation de stimulateurs et d'activateurs de la guanylate-cyclase soluble pour le traitement de la drépanocytose et la conservation de substituts sanguins

Info

Publication number
EP2585055A1
EP2585055A1 EP11726444.0A EP11726444A EP2585055A1 EP 2585055 A1 EP2585055 A1 EP 2585055A1 EP 11726444 A EP11726444 A EP 11726444A EP 2585055 A1 EP2585055 A1 EP 2585055A1
Authority
EP
European Patent Office
Prior art keywords
treatment
compounds
prophylaxis
formulas
cell anemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11726444.0A
Other languages
German (de)
English (en)
Inventor
Johannes-Peter Stasch
Eva-Maria Becker
Hubert TRÜBEL
Herbert Himmel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adverio Pharma GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Priority to EP13179993.4A priority Critical patent/EP2687210A1/fr
Priority to EP11726444.0A priority patent/EP2585055A1/fr
Publication of EP2585055A1 publication Critical patent/EP2585055A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Definitions

  • the present invention relates to the novel use of soluble guanylate cyclase stimulators and / or activators for the treatment of sickle cell anemia and the preservation of blood substitutes. Furthermore, the present invention relates to the use of soluble guanylate cyclase stimulators and / or activators in combination with PDE5 inhibitors for the treatment of sickle cell anemia and preservation of blood substitutes.
  • PH Pulmonary hypertension
  • Hb free hemoglobin
  • sGC soluble guanylate cyclase
  • transgenic mice exclusive expression of human sickle cell hemoglobin
  • PH various disease symptoms
  • sGC activators and stimulators for the treatment of sickle cell anemia and the associated PH as well as other pathologies (e.g., end-organ damage affecting the brain, kidney or heart).
  • an sGC activator and stimulator could in the future, the previously observed side effects [Weiskopf, Anesthesia & Analgesia, 110: 3; 659-661, 2010], which are due to reduced NO availability, mitigate and thus make a clinical application possible.
  • sGC activators and stimulators the soluble guanylate cyclase is directly stimulated, so that the missing NO effect is replaced.
  • sGC stimulators are not affected by free Hb.
  • sGC stimulators and sGC activators under acute and especially chronic conditions should show positive effects on blood pressure, oxygen saturation and the resulting plasma and tissue cGMP levels under experimental conditions.
  • These experimental conditions consist on the one hand of healthy animals, animals under external free Hb application or genetically modified animals such.
  • Sickle cell mice transgenic mice that exclusively express human sickle cell hemoglobin beta.
  • PDE5 inhibitors such as sildenafil, vardenaf il and Tadalafil repeatedly pointed to an increased occurrence of back pain. That's why it could be of extraordinary interest, o.g. sGC stimulators and activators can already be differentiated at the preclinical level of PDE 5 inhibitors.
  • the object of the present invention is to provide substances for the treatment of safeniaemia and preservation of blood substitutes.
  • the solution to this problem is to find the following sGC stimulators and / or sGC activators alone or in combination and the combination of sGC stimulators and / or sGC activators with PDE5 inhibitors.
  • cGMP cyclic guanosine monophosphate
  • NO nitric oxide
  • GTP guanosine triphosphate
  • the soluble guanylate cyclases consist of two subunits and most likely contain one heme per heterodimer that is part of the regulatory center. This is central to the activation mechanism. NO can bind to the iron atom of the heme and thus significantly increase the activity of the enzyme. On the other hand, heme-free preparations can not be stimulated by NO. Also, carbon monoxide (CO) is able to bind to the central iron atom of the heme, with stimulation by CO being significantly less than by NO.
  • CO carbon monoxide
  • guanylate cyclase plays a crucial role in various physiological processes, in particular in the relaxation and proliferation of smooth muscle cells, platelet aggregation and adhesion, neuronal signaling and diseases based on a disturbance of the above operations.
  • the NO / cGMP system may be suppressed, which may, for example, lead to hypertension, platelet activation, increased cell proliferation, endothelial dysfunction, arteriosclerosis, angina pectoris, heart failure, myocardial infarction, thrombosis, stroke and sexual dysfunction.
  • a NO-independent treatment option for such diseases which is aimed at influencing the cGMP pathway in organisms, is a promising approach on account of the expected high efficiency and low side effects.
  • the present invention is the use of soluble guanylate cyclase stimulators and / or activators for the treatment of sickle cell disease and preservation of blood substitutes.
  • pyrrolo [2,3-d] pyrimidin-6-one (24), 4-amino-5,5-dimethyl-2- [3- (2,4,6-trifluorobenzyl) imidazo [l, 5-a] pyridine -l-yl]] -5,7-dihydro-6H-pyrrolo [2,3-d] pyrimidin-6-one (25), 4-amino-2- [3- (2-cyclopentylethyl) imidazo [l, 5-a] pyridin-1-yl] -5,5-dimethyl-5,7-dihydro-6H-pyrrolo [2,3-d] pyrimidin-6-one (26) disclosed in WO 2010/065275. -6-
  • Another aspect of the invention is the combination of soluble guanylate cyclase stimulators and / or activators with PDE5 inhibitors for use in the treatment of sickle cell anemia and preservation of blood substitutes.
  • PDE5 inhibitors are suitable for combination for use in the treatment of sickle cell anemia and preservation of blood substitutes:
  • Tadalafil ((6R, 12aR) -2,3,6,7,12,12a - hexahydro - 2 - methyl - 6 - (3,4 - methylene - dioxyphenyl) pyrazino (1 ', 2': 1, 6) pyrido (3,4-b) indole-1, 4-dione), vardenafil (2- (2-ethoxy-5- (4-ethyl-piperazin-1-yl-1-sulfonyl) -phenyl) -5-methyl-7-propyl 3H-imidazo (5,1-f) (l, 2,4) triazin-4-one), sildenafil (3- [2-ethoxy-5- (4-methylpiperazin-1-yl) sulfonyl-phenyl] - 7-methyl-9-propyl-1,2,4,7,8-tetrazabicyclo [4.3.0] nona-3,8,10-trien-5-one),
  • the present invention is a process for the treatment and / or prophylaxis of sickle cell anemia and preservation of blood substitutes using a therapeutically effective amount of one or more of the compound of the invention according to the formulas (1) to (26).
  • Another object of the present invention is the use of one or more of the compounds of the invention according to the formulas (1) to (26) for the manufacture of a medicament for the treatment and / or prophylaxis of sickle cell anemia and preservation of blood substitutes.
  • Another object of the present invention is a pharmaceutical composition containing one or more compounds of the invention of formulas (1) to (26) and one or more other active ingredients, in particular for the treatment and / or prophylaxis of sickle cell anemia and preservation of blood substitutes.
  • Another object of the present invention is the use of one or more compounds of the formulas (1) to (26) in combination with one or more of the following PDE5 inhibitors: Tadalafil ((6R, 12aR) -2,3,6,7 , 12,12a - hexahydro - 2 - methyl - 6 - (3,4 - methylene - dioxyphenyl) pyrazino (l ', 2': l, 6) pyrido (3,4 - b) indole - l, 4 - dione) , Vardenafil (2- (2-ethoxy-5- (4-ethyl-piperazin-1-yl-1-sulfonyl) -phenyl) -5
  • Another object of the present invention is the use of one or more Verbidn 11, of formulas (3) to (7) according to claim 1 in combination with vardenafil and / or sildenafil for the treatment and / or prophylaxis of sickle cell anemia and preservation of blood substitutes.
  • Another object of the present invention is the use of one or more of the compounds of formulas (1) to (26) in combination with the abovementioned PDE5 inhibitors for the treatment and / or prophylaxis of traumatized patients who receive an artificial blood substitute.
  • Another object of the present invention is a method for the treatment and / or prophylaxis of sickle cell anemia and preservation of blood substitutes using a therapeutically effective amount of one or more compounds of the invention according to the formulas (1) to (26) in combination with the above-mentioned PDE5 inhibitors ,
  • Another object of the present invention is the use of one or more of the compounds of the invention according to the formulas (1) to (26) in combination with the above-mentioned PDE5 inhibitors for the manufacture of a medicament for the treatment and / or prophylaxis of sickle cell anemia and preservation of blood substitutes.
  • Another object of the present invention is a pharmaceutical composition containing one or more of the compounds of the invention formulas (1) to (26) in combination with the above-mentioned PDE5 inhibitors and one or more other active ingredients, in particular for the treatment and / or prophylaxis of sickle cell disease and preservation of blood substitutes.
  • Another object of the present invention is the use of one or more compounds of formulas (1) to (26) for the treatment and / or prophylaxis of sickle cell anemia wherein the application is by inhalation.
  • Another object of the present invention Use of one or more compounds of formulas (1) to (26) in combination with the above-mentioned PDE5 inhibitors for the treatment and / or prophylaxis of sickle cell anemia wherein the application is by inhalation.
  • NO and heme independent sGC activators were identified with the compound of formula (5) as the prototype of this class. Common characteristics of these substances are that in combination with NO they exert only an additive effect on the enzyme activation, and that the activation of the oxidized or heme-free enzyme is markedly stronger compared to the heme-containing enzyme [Evgenov et al., Ibid .; JP Stasch et al., Br. J. Pharmacol. 136 (2002), 773; JP Stasch et al., J. Clin. luvest. 116 (2006), 2552].
  • the compounds of the invention show an unpredictable, valuable pharmacological and pharmacokinetic activity spectrum.
  • the sGC stimulators and / or activators result in vasorelaxation and / or platelet aggregation inhibition and / or lowering blood pressure and / or increasing coronary blood flow and microcirculation in general to lead. They are therefore suitable for the treatment and / or prophylaxis of diseases, preferably of cardiovascular diseases, in humans and animals.
  • the compounds of the invention are therefore also suitable for the treatment of cardiovascular diseases such as for the treatment of hypertension, primary and / or secondary prevention and treatment of heart failure, for the treatment of stable and unstable angina pectoris, pulmonary hypertension, peripheral and cardial vascular diseases, arrhythmias Treatment of thromboembolic disorders and ischaemias such as myocardial infarction, stroke, transitory and ischemic attacks, peripheral circulatory disorders, prevention of restenosis such as after thrombolytic therapy, percutaneous transluminal angioplasty (PTA), percutaneous transluminal coronary angioplasty (PTCA) and bypass and for the treatment of arteriosclerosis, asthmatic disorders , Diseases of the genitourinary system such as prostatic hypertrophy, erectile dysfunction, female sexual dysfunction and incontinence are used.
  • cardiovascular diseases such as for the treatment of hypertension, primary and / or secondary prevention and treatment of heart failure
  • arrhythmias Treatment of thromboembolic disorders and ischaemias such as myocardi
  • the compounds of the invention may be used to treat primary and secondary Raynaud's phenomenon, microcirculatory disorders, claudication, peripheral and autonomic neuropathies, diabetic microangiopathies, diabetic nephropathy, diabetic retinopathy, diabetic ulcers on the extremities, CREST syndrome, erythematosis, onychomycosis, tinnitus, Dizziness, sudden hearing loss and rheumatic diseases.
  • the compounds according to the invention are suitable for the treatment of respiratory distress syndromes and chronic obstructive pulmonary diseases (COPD), of acute and chronic renal insufficiency and for the promotion of wound healing. Furthermore, the compounds according to the invention are also suitable for regulating cerebral blood flow and are effective agents for combating migraine. They are also suitable for the prophylaxis and control of the consequences of cerebral infarct events (Apoplexia cerebri) such as stroke, cerebral ischaemias and craniocerebral trauma , Likewise, the compounds of the invention can be used to combat pain.
  • COPD chronic obstructive pulmonary diseases
  • the compounds according to the invention can also be used for the treatment and / or prevention of micro- and macrovascular damage (vasculitis), reperfusion damage, arterial and venous thrombosis, edema, cancer (skin cancer, liposarcoma, carcinomas of the gastrointestinal tract, liver, pancreas , Lung, kidney, ureter, prostate and genital tract), diseases of the central nervous system and neurodegenerative disorders (stroke, Alzheimer's disease, Parkinson's disease, dementia, epilepsy, depression, multiple sclerosis), inflammatory diseases, immune diseases (Morbus Crohn's disease, ulcerative colitis, lupus erythematosus, rheumatoid arthritis, asthma), kidney disease (glomerulonephritis), thyroid disease (hyperthyroidism), diseases of the pancreas (pancreatitis), liver fibrosis, skin diseases (psoriasis, acne, eczema, atopic dermatitis, dermatitis,
  • Another object of the present invention is the use of the compounds of the invention for the treatment and / or prophylaxis of diseases, preferably of thromboembolic diseases and / or thromboembolic complications.
  • thromboembolic disorders include in particular diseases such as heart attack with ST segment elevation (STEMI) and without ST segment elevation (non-STEMI), stable angina pectoris, unstable angina pectoris, reocclusions and restenosis following coronary interventions such as angioplasty, stent or aortocoronary bypass, peripheral arterial occlusive disease, pulmonary embolism, deep venous thrombosis and renal vein thrombosis, transient ischemic attacks, and thrombotic and thromboembolic stroke and pulmonary hypertension.
  • diseases such as heart attack with ST segment elevation (STEMI) and without ST segment elevation (non-STEMI)
  • stable angina pectoris such as unstable angina pectoris, reocclusions and restenosis following coronary interventions such as angioplasty, stent or aortocoronary bypass, peripheral arterial occlusive disease, pulmonary embolism, deep venous thrombosis and renal vein thrombosis, transient
  • the substances are therefore also useful in the prevention and treatment of cardiogenic thromboembolism, such as brain ischemia, stroke and systemic thromboembolism and ischaemia, in patients with acute, intermittent or persistent cardiac arrhythmias, such as atrial fibrillation, and those who undergo cardioversion, further in patients with valvular disease or with intravascular bodies such.
  • cardiogenic thromboembolism such as brain ischemia, stroke and systemic thromboembolism and ischaemia
  • cardiac arrhythmias such as atrial fibrillation
  • intravascular bodies such as atrial fibrillation
  • Artificial heart valves, catheters, intra-aortic balloon counterpulsation and pacemaker probes are suitable for the treatment of disseminated intravascular coagulation (DIC).
  • DIC disseminated intravascular coagulation
  • Thromboembolic complications also occur in microangiopathic hemolytic anemias, sickle cell anemia, thalassemia, inherited forms of spherocytosis, elliptocytosis and ovalcytosis, malaria, Moskowitch syndrome, hemolytic uraemia syndrome, extracorporeal blood circulation, such as.
  • hemofiltration, ventricular assist devices and artificial heart, and heart valve prostheses, blood transfusions, cardiopulmonary bypass and organ transplantation eg lung, heart, kidney, liver
  • the compounds according to the invention are also particularly suitable for primary and / or secondary prevention and treatment of cardiac insufficiency.
  • cardiac insufficiency also encompasses more specific or related forms of disease such as right heart failure, left heart failure, global insufficiency, ischemic cardiomyopathy, dilated cardiomyopathy, congenital heart defects, valvular heart failure, valvular heart failure, mitral valve stenosis, mitral valve insufficiency, aortic valve stenosis, aortic valve insufficiency, tricuspid stenosis, tricuspid insufficiency, pulmonary valve stenosis, Pulmonary valvular insufficiency, combined heart valve defects, myocarditis, chronic myocarditis, acute myocarditis, viral myocarditis, diabetic heart failure, alcoholic cardiomyopathy, cardiac storage disorders, diastolic heart failure, and systolic heart failure.
  • Another object of the present invention is the use of the compounds of the invention for the treatment and / or prophylaxis of diseases
  • the present invention is also suitable for the treatment of traumatized patients who receive an artificial blood substitute [Weisskopf 2010].
  • Another object of the present invention is the use of the compounds of the invention for the manufacture of a medicament for the treatment and / or prophylaxis of diseases, in particular the aforementioned diseases.
  • Another object of the present invention is a method for the treatment and / or prophylaxis of diseases, in particular the aforementioned diseases, using a therapeutically effective amount of a compound of the invention.
  • Another object of the present invention is the use of the compounds of the invention for the manufacture of a medicament for the treatment and / or prophylaxis of sickle cell anemia and preservation of blood substitutes.
  • Another object of the present invention is a method for the treatment and / or prophylaxis of sickle cell anemia and preservation of blood substitutes, using a therapeutically effective amount of a compound of the invention.
  • the compounds of the invention may be used alone or as needed in combination with other agents.
  • Another object of the present invention are pharmaceutical compositions containing a compound of the invention and one or more other active ingredients, in particular for the treatment and / or prophylaxis of the aforementioned diseases.
  • suitable combination active ingredients are lipid metabolism-altering active substances, antidiabetic drugs, blood pressure depressants, circulation-promoting and / or antithrombotic agents, antioxidants, aldosterone and mineralocorticoid receptor antagonists, vasopressin receptor antagonists, organic nitrates and NO.
  • IP receptor agonists positive inotropic compounds, ACE inhibitors, cGMP and cAMP modulating compounds, neutrophilic ecstasis inhibitors, signal transduction cascade inhibiting compounds, heart energy modulating compounds, chemokine receptor antagonists, p38 kinase inhibitors, NPY agonists, orexin agonists, anorectics, PAF-AH Inhibitors, antiphlogistics (COX inhibitors, LTB 4 receptor antagonists, LTB 4 synthesis inhibitors), analgesics (aspirin), antidepressants and other psychotropic drugs.
  • COX inhibitors antiphlogistics
  • LTB 4 receptor antagonists LTB 4 synthesis inhibitors
  • analgesics aspirin
  • antidepressants other psychotropic drugs.
  • the present invention relates, in particular, to combinations with at least one of the compounds according to the invention having at least one active ingredient which alters the lipid metabolism, an antidiabetic agent, a hypotensive agent and / or an antithrombotic agent.
  • the compounds of the invention may preferably be with one or more
  • the fat metabolism-altering active substances by way of example and preferably from the group of HMG-CoA reductase inhibitors from the class of statins, such as, for example and preferably, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin,
  • CETP inhibitors such as, by way of example and by way of preference, torcetrapib, JTT-705 or CETP vaccine (Avant), PPAR- ⁇ and / or PPAR-8 agonists such as, by way of example and preferably, pioglitazone or rosiglitazone and / or GW-501516, RXR modulators , FXR modulators, LXR modulators, thyroid hormones and / or thyroid mimetics such as, by way of example and by way of preference, D-thyroxine or 3,5,3'-triiodothyronine (T3), ATP citrate lyase inhibitors,
  • Lp (a) antagonists cannabinoid receptor 1 antagonists such as by way of example and preferably rimonabant or SR-147778, leptin receptor agonists, bombesin receptor agonists, histamine receptor agonists, agonists of the niacin receptor, for example and preferably niacin, Acipimox, A mecanical or Radecol, as well as the antioxidants / free-radical scavengers as exemplified and preferably probucol, AGI-1067, BO-653 or AEOL-
  • Insulin and insulin derivatives are preferably insulin and insulin derivatives as well as orally active hypoglycemic Understood agents.
  • Insulin and insulin derivatives here include both insulins of animal, human or biotechnological origin as well as mixtures thereof.
  • the orally active hypoglycemic agents preferably include sulphonylureas, biguanides, meglitinide derivatives, glucosidase inhibitors and PPAR-gamma agonists, and by way of example and preferably those from the group of sulphonylureas, such as by way of example and preferably tolbutamide, glibenclamide, glimepiride, glipizide or gliclazide, biguanides , such as by way of example and with preference metformin, meglitinide derivatives, such as by way of example and preferably repaglinide or nateglinide, glucosidase inhibitors, such as by way of example and preferably miglitol or acarbose, oxadiazolidinones, thiazolidinediones, GLP 1 receptor agonists, glucagon antagonists, insulin sensitizers, CCK 1 receptor
  • hypotensive agents by way of example and preferably from the group of calcium antagonists such as, by way of example and by way of preference, nifedipine, amlodipine, verapamil or diltiazem, angiotensin AII antagonists such as, for example and preferably, losartan, valsartan, candesartan, embusartan or telmisartan, ACE inhibitors , as exemplified and preferably, enalapril, captopril, ramipril, delapril, fosinopril, quinopril, perindopril or trandopril, beta-receptor blockers such
  • Sympathetic tone lowering agents such as, for example and preferably, reserpine, clonidine or alpha-methyl-dopa, or in combination with a potassium channel agonist, such as, for example and preferably, minoxidil, diazoxide, dihydralazine or hydralazine;
  • Antithrombotic agents by way of example and preferably from the group of platelet aggregation inhibitors, such as by way of example and preferably aspirin, clopidogrel, ticlopidine, cilostazol or dipyridamole, or the anticoagulants such as thrombin inhibitors, such as by way of example and preferably ximelagatran, melagatran, bivalirudin or Clexane, a GPIIb / IIIa antagonist such as, by way of example and preferably, tirofiban or abciximab, a factor Xa inhibitor such as, by way of example and by way of preference, rivaroxaban (BAY 59-7939), DU-176b, apixaban , Otamixaban, Fidexaban, Razaxaban, Fondaparinux, Idraparinux, PMD-3112, YM-150, KFA-1982, EMD-503982, MCM-17, MLN-10
  • SSR-126512 or SSR-128428 with heparin or a low molecular weight (LMW) heparin derivative or with a vitamin K antagonist, such as by way of example and preferably coumarin,
  • Aldosterone and mineralocorticoid receptor antagonists such as by way of example and preferably spironolactone or eplerenone;
  • Vasopressin receptor antagonists such as by way of example and preferably Conivaptan, Tolvaptan, Lixivaptan or SR-121463;
  • Organic nitrates and NO donors such as, for example, sodium nitroprusside, nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, molsidomine or SIN-1, or in combination with inhaled NO;
  • IP receptor agonists such as, by way of example, and iloprost, treprostinil, beraprost, and NS-304
  • Positive inotropic compounds such as, by way of example and by way of illustration, cardiac glycosides (digoxin), beta-adrenergic and dopaminergic agonists such as isoproterenol, epinephrine, norepinephrine, dopamine or dobutamine;
  • Calcium sensitizers such as by way of example and preferably levosimendan
  • cGMP cyclic guanosine monophosphate
  • cAMP cyclic adenosine monophosphate
  • PDE phosphodiesterases
  • sildenafil sildenafil
  • Vardenafil tadalafil
  • PDE 3 inhibitors such as milrinone
  • Natriuretic peptides such as “atrial natriuretic peptide” (ANP, anaritide), "B-type natriuretic peptide” or “brain natriuretic peptide” (BNP, nesiritide), "C-type natriuretic peptide” (CNP) and urodilatin; NO-independent, but heme-dependent guanylate cyclase stimulators, in particular the compounds described in WO 00/06568, WO 00/06569, WO 02/42301 and WO 03/095451;
  • Guanylate cyclase NO- and heme-independent activators in particular the compounds described in WO 01/19355, WO 01/19776, WO 01/19778, WO 01/19780, WO 02/070462 and WO 02/070510;
  • HNE human neutrophilic ecstasy
  • the signal transduction cascade inhibiting compounds such as tyrosine kinase inhibitors and multikinase inhibitors, in particular sorafenib, imatinib, gefitinib and
  • Compounds influencing the energy metabolism of the heart such as, for example, estimoxir, dichloroacetate, ranolazine and trimetazidine.
  • Particularly preferred in the context of the present invention are combinations containing at least one of the compounds according to the invention and one or more further active ingredients selected from the group consisting of HMG-CoA reductase inhibitors (statins), diuretics, antidiabetics, beta-receptor blockers, organic nitrates and NO donors, ACE inhibitors, angiotensin AII antagonists, aldosterone and mineralocorticoid receptor antagonists, vasopressin receptor antagonists, platelet aggregation inhibitors and anticoagulants, and their use for the treatment and / or prevention of the aforementioned disorders.
  • HMG-CoA reductase inhibitors statins
  • diuretics antidiabetics
  • beta-receptor blockers organic nitrates and NO donors
  • ACE inhibitors angiotensin AI
  • the compounds according to the invention can act systemically and / or locally.
  • they may be applied in a suitable manner, e.g. oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, dermal, transdermal, conjunctival, otic or as an implant or stent.
  • the compounds according to the invention can be administered in suitable administration forms.
  • the compounds of the invention in crystalline and / or amorphized and / or dissolved form such as tablets (uncoated or coated tablets, for example with enteric or delayed-dissolving or insoluble coatings which control the release of the compound of the invention), orally disintegrating tablets or films / wafers, films / lyophilisates, capsules (e.g. Hard or soft gelatin capsules), dragees, granules, pellets, powders, emulsions, suspensions, aerosols or solutions.
  • tablets uncoated or coated tablets, for example with enteric or delayed-dissolving or insoluble coatings which control the release of the compound of the invention
  • orally disintegrating tablets or films / wafers, films / lyophilisates capsules (e.g. Hard or soft gelatin capsules), dragees, granules, pellets, powders, emulsions, suspensions, aerosols or solutions.
  • Parenteral administration can be accomplished by bypassing a resorption step (e.g., intravenously, intraarterially, intracardially, intraspinal, or intralumbar) or by resorting to absorption (e.g., intramuscularly, subcutaneously, intracutaneously, percutaneously, or intraperitoneally).
  • a resorption step e.g., intravenously, intraarterially, intracardially, intraspinal, or intralumbar
  • absorption e.g., intramuscularly, subcutaneously, intracutaneously, percutaneously, or intraperitoneally.
  • parenteral administration are suitable as application forms u.a. Injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
  • the oral application is preferred.
  • Inhalation medicines including powder inhalers, nebulizers
  • nasal drops solutions, sprays
  • lingual, sublingual or buccal tablets films / wafers or capsules
  • suppositories ear or ophthalmic preparations
  • vaginal capsules aqueous suspensions (lotions, shake mixtures)
  • lipophilic suspensions ointments
  • creams transdermal therapeutic systems (such as patches)
  • milk Pastes, foams, scattering powders, implants or stents.
  • the compounds according to the invention can be converted into the stated administration forms. This can be done in a conventional manner by mixing with inert, non-toxic, pharmaceutically suitable excipients.
  • These adjuvants include, among others. Carriers (for example microcrystalline cellulose, lactose, mannitol), solvents (for example liquid polyethylene glycols), emulsifiers and dispersants or wetting agents (for example sodium dodecyl sulfate, polyoxysorbitanoleate), binders (for example polyvinylpyrrolidone), synthetic and natural polymers (for example albumin), stabilizers ( For example, antioxidants such as ascorbic acid), dyes (eg, inorganic pigments such as iron oxides) and flavor and / or odoriferous.
  • Carriers for example microcrystalline cellulose, lactose, mannitol
  • solvents for example liquid polyethylene glycols
  • emulsifiers and dispersants or wetting agents for example sodium dodecy
  • compositions containing at least one inventive compound preferably together with one or more inert non-toxic, pharmaceutically suitable excipient, as well as their use for the treatment of sickle cell anemia and preservation of blood substitutes.
  • parenterally administered amounts of about 5 to 100 mg per 24 hours to achieve effective results.
  • the amount is about 5 to 250 mg per 24 hours.
  • Method 1 Device Type MS: Waters ZQ; Device Type HPLC: Agilent 1100 Series; UV DAD; Column: Thermo Hypersil GOLD 3 ⁇ 20 mm x 4 mm; Eluent A: 1 l of water + 0.5 ml of 50% formic acid, eluent B: 1 l of acetonitrile + 0.5 ml of 50% strength formic acid; Gradient: 0.0 min 100% A -> 3.0 min 10% A -> 4.0 min 10% A -> 4.1 min 100% A (flow 2.5 ml / min); Oven: 55 ° C; Flow: 2 ml / min; UV detection: 210 nm.
  • Method 2 Instrument: Waters ACQUITY SQD UPLC System; Column: Waters Acquity UPLC HSS T3 1.8 ⁇ 50 x 1 mm; Eluent A: 1 l of water + 0.25 ml of 99% formic acid, eluent B: 1 l of acetonitrile + 0.25 ml of 99% formic acid; Gradient: 0.0 min 90% A -> 1.2 min 5% A -> 2.0 min 5% A Furnace: 50 ° C; Flow: 0.40 ml / min; UV detection: 210 - 400 nm.
  • the diazonium salt thus prepared was added in portions to a 0 ° C cold solution of 12.81 g (85.45 mmol) of sodium iodide in acetone (329 ml) and the mixture stirred for 30 min at RT.
  • the reaction mixture was added to ice water (1.8 L) and extracted twice with ethyl acetate (487 mL each).
  • the collected organic phases were washed with saturated aqueous sodium chloride solution (244 ml), dried, filtered and concentrated. This gave 12.1 g (86% purity, 60% of theory) of the desired compound as a brown solid.
  • the crude product was reacted without further purification.
  • the aqueous phase was separated and extracted twice more with ethyl acetate (200 ml each time).
  • the combined organic phases were washed twice with 10% aqueous sodium chloride solution (100 ml each), dried and concentrated in vacuo.
  • the crude product was reacted without further purification.
  • Variant B Preparation starting from Example 10A: 39.23 g (85.75 mmol) of the compound from Example 10A were initially charged in DMF (800 ml) and then 4 g of palladium (10% on carbon) were added. It was hydrogenated with stirring overnight at normal hydrogen pressure. The mixture was filtered through kieselguhr and washed with a little DMF and then with a little methanol and concentrated to dryness. The residue was combined with ethyl acetate and stirred vigorously, the precipitate was filtered off with suction, washed with ethyl acetate and diisopropyl ether and dried over Sicapent under high vacuum.
  • 29 ⁇ M enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to Hönicka et al., J. Mol. Med. 77, 14-23 (1999)) in 50 mM TEA, 2 mM MgCl 2 , 0.1%. BSA (fraction V), 0.005%> Brij ®, pH 7.5] placed in a microplate and 1 ⁇ of the substance to be tested is added (as a serially diluted solution in DMSO). The mixture is incubated for 10 min at room temperature.
  • the enzyme reaction is started by adding 20 straten ⁇ sub- [1.25 mM guanosine 5'-triphosphate (Fa. Sigma) in 50 mM TEA, 2 mM MgCl 2, 0.1%> BSA (fraction V), 0.005%) Brij ®, pH 7.5] and continuously measured luminometrically.
  • the degree of stimulation by the substance to be tested can be determined relative to the signal of the non-stimulated reaction.
  • the cellular activity of the compounds of the invention is measured on a recombinant guanylate cyclase reporter cell line as described in F. Wunder et al., Anal. Biochem. 339, 104-112 (2005). l.c vascular relaxatory effect in vitro
  • aorta Rabbits are stunned and bled by a stroke of the neck.
  • the aorta is harvested, detached from adherent tissue, divided into 1.5 mm wide rings and placed individually under bias in 5 ml organ baths with 37 ° C warm, carbogen-gassed Krebs-Henseleit solution of the following composition (in each case mM): Sodium chloride: 119; Potassium chloride: 4.8; Calcium chloride dihydrate: 1; Magnesium sulfate heptahydrate: 1 .4; Potassium dihydrogen phosphate: 1 .2; Sodium hydrogencarbonate: 25; Glucose: 10.
  • the force of contraction is detected with Statham UC2 cells, amplified and digitized via A / D converter (DAS-1802 HC, Keithley Instruments Munich) and registered in parallel on a chart recorder.
  • a / D converter DAS-1802 HC, Keithley Instruments Munich
  • phenylephrine is added cumulatively to the bath in increasing concentration.
  • the substance to be examined is added in each subsequent passage in increasing doses and the height of the contraction is compared with the height of the contraction achieved in the last predistortion. This is used to calculate the concentration required to reduce the level of the control value by 50% (IC 50 value).
  • the standard application volume is 5 ⁇ , the DMSO content in the bath solution corresponds to 0.1%. 2.
  • a commercially available telemetry system from DATA SCIENCES INTERNATIONAL DSI, USA is used for the blood pressure measurement on awake rats described below.
  • the system consists of 3 main components: - Implantable transmitters (Physiotel® telemetry transmitters)
  • Data acquisition computer are connected.
  • the telemetry system allows a continuous recording of blood pressure heart rate and body movement on awake animals in their habitual habitat.
  • the experimental animals are kept individually in macroion cages type 3 after transmitter implantation. You have free access to standard food and water.
  • the day - night rhythm in the experimental laboratory is changed by room lighting at 6:00 in the morning and at 19:00 in the evening.
  • the TAI 1 PA - C40 telemetry transmitters are surgically implanted at least 14 days before the first attempt under aseptic conditions.
  • the animals so instrumented are repeatedly used after healing of the wound and ingrowth of the implant.
  • the fasting animals are anaesthetized with pentobabital (Nembutal, Sanofi: 50 mg / kg ip) and shaved and disinfected on the ventral side.
  • pentobabital Nembutal, Sanofi: 50 mg / kg ip
  • the system's liquid-filled measuring catheter above the bifurcation is inserted cranially into the descending aorta and secured with tissue adhesive (VetBonD TM, 3M).
  • the transmitter housing is fixed intraperitoneally to the abdominal wall musculature and the wound is closed in layers.
  • an antibiotic is administered for infection prophylaxis (Tardomyocel COMP Bayer 1 ml / kg sc)
  • a solvent-treated group of animals is used as a control.
  • Experimental procedure The existing telemetry measuring device is configured for 24 animals. Each trial is registered under a trial number (VYear month day).
  • the instrumented rats living in the plant each have their own receiving antenna (1010 receivers, DSI).
  • the implanted transmitters can be activated externally via a built-in magnetic switch. They will be put on the air during the trial run.
  • the emitted signals can be recorded online by a data acquisition system (Dataquest TM A.R.T. for Windows, DSI) and processed accordingly. The storage of the data takes place in each case in a folder opened for this purpose which carries the test number.
  • SBP Systolic blood pressure
  • ACT Activity - Activity
  • the measured value acquisition is repeated computer-controlled in 5-minute intervals.
  • the absolute value of the source data is corrected in the diagram with the currently measured barometric pressure (Ambient Pressure Reference Monitor, APR-1) and in individual data stored. Further technical details can be found in the extensive documentation of the manufacturer (DSI).
  • test substances will take place at 9 o'clock on the day of the experiment. Following the application, the parameters described above are measured for 24 hours.
  • the collected individual data are sorted with the analysis software (DATAQUEST TM A.RT. TM ANALYSIS).
  • the blank value is assumed here 2 hours before application, so that the selected data set covers the period from 7:00 am on the day of the experiment to 9:00 am on the following day.
  • the data is smoothed over a presettable time by averaging (15 minutes average) and transferred as a text file to a disk.
  • the presorted and compressed measured values are transferred to Excel templates and displayed in tabular form.
  • the filing of the collected data takes place per experiment day in a separate folder that bears the test number. Results and test reports are sorted in folders and sorted by paper.
  • the blood pressure and the heart rat By introducing a PE50 arterial catheter into the left femoral artery, the blood pressure and the heart rat (Transducer Ref. 5203660: Fa. Braun CH).
  • the substance is administered as a bolus or continuous infusion via a venous catheter in the left femoral vein.
  • the right external iliac artery is ligated under sterile conditions.
  • anesthetic conditions e.g., inhalation anesthesia, isoflurane, enflurane
  • the femoral artery must be additionally ligated in order to produce a less perfusion.
  • the test animals are treated orally, intragastrically (gastric tube, feed or drinking water intake), intraperitoneally, intravenously, intraarterially, intramuscularly, by inhalation or subcutaneously with the test substances.
  • extracellular hemoglobin previously obtained from donor animals, is applied to the animals.
  • test substances are administered acute or once or several times daily for up to 5 weeks, enterally or parenterally daily, or are administered over subcutaneously implanted osmotic minipumps (e.g., Alzet pumps). Microperfusion and temperature of the lower extremities are documented during the trial.
  • the rats are under anesthesia, a temperature-sensitive laser Doppler probe (Periflux) glued to the paws and thus measured micro perfusion and skin temperature.
  • samples such as blood (interim diagnosis) and other body fluids or organs are taken to perform further in vitro tests or blood pressure and heart rate are measured via a catheter in the carotid artery for documentation of hemodynamics.
  • the animals are killed painlessly.
  • mice eg, eNOS knock out mice, wild-type mice C-57 B16 or ApoE knock out mice, sickle cell mice, .
  • mice were caged and trained in cages with an impeller 4-5 weeks before the start of the experiment. Two weeks before the start of the experiment, the movements of the mice in the impeller are recorded by a photocell using a computer and various running parameters such as the daily running distance, the individual distances covered, but also their temporal distribution over the day.
  • the animals are randomized according to their natural running behavior in groups (8-12 animals) (control group, sham group and one or more substance groups).
  • test animals are administered orally, intragastrically (gastric tube, feed or drinking water intake), intraperitoneally, intravenously, intraarterially, intramuscularly, by inhalation or subcutaneously with the Treated test substances.
  • the test substances are administered once or several times daily or repeatedly enterally or parenterally daily for up to 5 weeks or there is a continuous application via subcutaneously implanted osmotic minipumps.
  • the running behavior of the animals is observed and recorded over 5-8 weeks.
  • the animals are killed painlessly.
  • samples such as blood and other body fluids or organs are taken to carry out further in vitro investigations (S. Vogelsberger New animal models for the indication Claudicatio Intermittens (Paperback), Publisher: WB Laufersweiler Verlag (March 2006), ISBN 10: 383595007X , ISBN-13: 978-3835950078).
  • hemodynamics in anesthetized dogs are 25-35 kg healthy or heart failure Mongrel dogs ® (Marshall BioResources, Marshall Farms Inc; Clyde NY, USA) both sexes used.
  • the anesthesia is induced by slow intravenous administration of 25 mg / kg of sodium thiopental (Trapanal ®) and 0:15 mg / kg Alcuronium chloride (Alloferin ®) and during the experiment maintained by a continuous infusion of 12:04 mg / kg * h fentanyl (Fentanyl ®) , 0.25 mg / kg * h Droperidol (Dihydrobenzperidol ® ) and 15 ⁇ g / kg / h Alcuronium Chloride (Alloferin ® ).
  • the animals are ventilated via the ventilator with a constant breathing volume, so that an end-tidal CO 2 concentration of about 5% is achieved. Ventilation takes place with room air, enriched with approx. 30% oxygen (normoxie).
  • a catheter filled with fluid is implanted in the femoral artery to measure blood pressure.
  • a 2-lumiger Swan-Ganz catheter is ® jugularis on the V. into the pulmonary artery washed in (distal lumen for measuring the pulmonary arterial pressure, proximal lumen for measuring the central venous pressure).
  • a temperature sensor at the tip of the catheter determines the continuous cardiac output (CCO).
  • the blood flow is measured on different vascular beds such as the coronary artery, the carotid artery or the femoral artery by attaching flow probes (Transonic Flowprobe) to the respective vessels.
  • the hnksventrikuläre pressure is measured after the introduction of a Mikro-Tip catheter (Millar Instruments ®) through the carotid artery into the left ventricle and, derived from the dP / dt as a measure of contractility.
  • Substances are administered iv via the femoral vein or intraduodenally as a cumulative dose-response curve (bolus or continuous infusion).
  • the hemodynamic signals are recorded and evaluated by means of pressure transducers / amplifiers and PONEMAH ® as data acquisition software.
  • a pacemaker is implanted into the dogs under sterile conditions. After induction of anesthesia with pentobarbital-Na (15 to 30 mg kg -1 iv) followed by intubation and subsequent ventilation (room air, Sulla 808, Dräger® , Germany) Anesthesia maintained by continuous infusion of pentobarbital (1-5 mg kg "1 h " 1 ) and fentanyl (10-40 ⁇ g kg "1 h " 1 ). A pacing lead (Setrox S60 ®, Biotronik, Germany) is implanted placed over an insertion of the left jugular vein and the right ventricle.
  • the cable is connected to the pacemaker ( Logos® , Biotronik, Germany), which is positioned in a small subcutaneous pocket between the shoulder blades. Only 7 days after the procedure, ventricular pacing to achieve heart failure is started at a rate of 220 beats / min for a period of 10-28 days.
  • the pacemaker logos® , Biotronik, Germany
  • Hemodynamic parameters were continuously measured by intravascular catheters connected by Combitrans® transducers to Gould® transducers (series 6600) connected to the PoNeMah® acquisition and analysis system.
  • Ventilation takes place with room air enriched with approx. 40% oxygen (Normoxie).
  • catheters are inserted into the femoral artery for blood pressure measurement and a Swan- Ganz® catheter is inserted through the jugular vein into the pulmonary artery (distal lumen for measurement of pulmonary artery pressure, proximal lumen for measurement of central venous pressure).
  • a temperature sensor at the tip of the catheter determines the continuous cardiac output (CCO).
  • CO continuous cardiac output
  • the hemodynamic signals are recorded and evaluated by means of pressure transducers / amplifiers and PONEMAH ® as data acquisition software. 2.g.) Inhalation of sGC simulators and activators
  • Acute pulmonary hypertension was induced by a thromboxane A2 analogue infusion (0.12-0.14 ⁇ g / kg / min 9,11 -dideoxy-9a, 11 ⁇ -epoxymethanoprostaglandin F2a (U-46619, Sigma, Germany)) or monocrotaline administration in rats of the Substances were carried out using the Nebutec® or Aeroneb® Pro Vernebier system or after solid nebulization (Pauluhn), which were switched into the inspiratory limb of the respiration. The substances were used as solids or solutions depending on the molecular structure. The hemodynamic signals are recorded and evaluated by means of pressure transducers / amplifiers and PONEMAH ® or CardioMems ® as data acquisition software.
  • Hot Plate Type Socrel DS 37, Ugo Basile Co.
  • mice e.g., NMRI jaws, sickle cell mice.
  • the temperature of the hot plate is 50 ° C, the maximum duration of measurement per animal 90 seconds (cut off time).
  • a hot plate pre-value is determined for each animal. Criteria for latency (in sec.) To the pain reaction are paw shaking, paw licking or jumping. After administration of the test substance for about 8 days, the second test result is carried out under the same conditions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

L'invention concerne l'utilisation nouvelle de stimulateurs et d'activateurs de la guanylate-cyclase soluble pour le traitement de la drépanocytose et la conservation de substituts sanguins. L'invention concerne également l'utilisation de stimulateurs et d'activateurs de la guanylate-cyclase soluble en combinaison avec des inhibiteurs de PDE 5 pour le traitement de la drépanocytose et la conservation de substituts sanguins.
EP11726444.0A 2010-06-25 2011-06-21 Utilisation de stimulateurs et d'activateurs de la guanylate-cyclase soluble pour le traitement de la drépanocytose et la conservation de substituts sanguins Withdrawn EP2585055A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP13179993.4A EP2687210A1 (fr) 2010-06-25 2011-06-21 Stimulateurs et activateurs de la guanylate cyclase soluble pour leur utilisation dans le traitement de la drépanocytose et de la conservation des substituts sanguins
EP11726444.0A EP2585055A1 (fr) 2010-06-25 2011-06-21 Utilisation de stimulateurs et d'activateurs de la guanylate-cyclase soluble pour le traitement de la drépanocytose et la conservation de substituts sanguins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10006623 2010-06-25
EP11726444.0A EP2585055A1 (fr) 2010-06-25 2011-06-21 Utilisation de stimulateurs et d'activateurs de la guanylate-cyclase soluble pour le traitement de la drépanocytose et la conservation de substituts sanguins
PCT/EP2011/060331 WO2011161099A1 (fr) 2010-06-25 2011-06-21 Utilisation de stimulateurs et d'activateurs de la guanylate-cyclase soluble pour le traitement de la drépanocytose et la conservation de substituts sanguins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP13179993.4A Division EP2687210A1 (fr) 2010-06-25 2011-06-21 Stimulateurs et activateurs de la guanylate cyclase soluble pour leur utilisation dans le traitement de la drépanocytose et de la conservation des substituts sanguins

Publications (1)

Publication Number Publication Date
EP2585055A1 true EP2585055A1 (fr) 2013-05-01

Family

ID=44358005

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11726444.0A Withdrawn EP2585055A1 (fr) 2010-06-25 2011-06-21 Utilisation de stimulateurs et d'activateurs de la guanylate-cyclase soluble pour le traitement de la drépanocytose et la conservation de substituts sanguins
EP13179993.4A Withdrawn EP2687210A1 (fr) 2010-06-25 2011-06-21 Stimulateurs et activateurs de la guanylate cyclase soluble pour leur utilisation dans le traitement de la drépanocytose et de la conservation des substituts sanguins

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP13179993.4A Withdrawn EP2687210A1 (fr) 2010-06-25 2011-06-21 Stimulateurs et activateurs de la guanylate cyclase soluble pour leur utilisation dans le traitement de la drépanocytose et de la conservation des substituts sanguins

Country Status (4)

Country Link
US (1) US20130158028A1 (fr)
EP (2) EP2585055A1 (fr)
CA (1) CA2803688A1 (fr)
WO (1) WO2011161099A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3002298T (lt) 2007-11-21 2019-12-10 Univ Oregon Health & Science Monokloniniai antikūnai prieš faktorių xi ir jų panaudojimo būdai
HUE042940T2 (hu) 2008-12-18 2019-07-29 Univ Oregon Health & Science Anti-FXI antitestek és alkalmazási eljárások
BR112013000596A2 (pt) 2010-07-09 2019-09-24 Bayer Intelectual Property Gmbh piridinas e tiazinas fusionadas e seus usos.
US8569339B2 (en) * 2011-03-10 2013-10-29 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
JP6140738B2 (ja) * 2012-03-06 2017-05-31 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換アザ二環およびその使用
AU2013258043B2 (en) 2012-05-10 2017-11-30 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor XI and/or its activated form factor XIa and uses thereof
KR102137517B1 (ko) 2012-07-20 2020-07-24 바이엘 파마 악티엔게젤샤프트 신규 5-아미노테트라히드로퀴놀린-2-카르복실산 및 그의 용도
US8906904B2 (en) 2012-09-07 2014-12-09 Boehringer Ingelheim International Gmbh Alkoxy pyrazoles as soluble guanylate cyclase activators
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
EP2927231B1 (fr) * 2012-11-30 2017-09-20 Astellas Pharma Inc. Composés imidazopyridine
AU2014222739A1 (en) 2013-03-01 2015-09-03 Bayer Pharma Aktiengesellschaft Trifluormethyl-substituted ring-fused pyrimidines and use thereof
WO2015004105A1 (fr) 2013-07-10 2015-01-15 Bayer Pharma Aktiengesellschaft Benzyl-1h-pyrazolo[3,4-b]pyridine et utilisation de cette dernière
EP3024455A1 (fr) 2013-07-25 2016-06-01 Bayer Pharma Aktiengesellschaft Stimulateurs de sgc ou activateurs de sgc et inhibiteurs de pde5 en combinaison avec un autre traitement pour la thérapie de la fibrose kystique
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
WO2016014463A1 (fr) 2014-07-22 2016-01-28 Boehringer Ingelheim International Gmbh Acides carboxyliques hétérocycliques en tant qu'activateurs de la guanylate cyclase soluble
CN108473470A (zh) 2015-12-18 2018-08-31 诺华股份有限公司 作为可溶性鸟苷酸环化酶激活剂的茚满衍生物及其用途
CN109890379A (zh) 2016-10-11 2019-06-14 拜耳制药股份公司 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品
CN110022871A (zh) 2016-10-11 2019-07-16 拜耳制药股份公司 包含sGC刺激物和盐皮质激素受体拮抗剂的组合产品
CN108069960A (zh) * 2016-11-15 2018-05-25 江苏豪森药业集团有限公司 利奥西呱中间体的制备方法
CN108690016B (zh) * 2017-04-11 2022-08-12 广东东阳光药业有限公司 吡唑并吡啶类化合物及其用途
CN110305125B (zh) * 2019-06-06 2021-09-03 山东新华制药股份有限公司 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011727A1 (fr) * 2003-08-01 2005-02-10 Pfizer Limited Combinaison d'un activateur de cyclase de guanylate soluble et d'un inhibiteur d'ace utile dans le traitement d'un trouble cardio-vasculaire ou metabolique
WO2007039155A2 (fr) * 2005-10-06 2007-04-12 Bayer Healthcare Ag Utilisation d'activateurs de la cyclase de guanylate destinee a traiter des maladies pulmonaires aigues et chroniques
WO2010144477A2 (fr) * 2009-06-12 2010-12-16 Auspex Pharmaceuticals, Inc. Modulateurs sulfonylurée du récepteur de l'endothéline
WO2011115804A1 (fr) * 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Stimulateurs de sgc

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380945A (en) * 1989-06-21 1995-01-10 Abbott Laboratories Guanidino compounds as regulators of nitric oxide synthase
CA2241567A1 (fr) 1996-01-17 1997-07-24 Novo Nordisk A/S Derives de 1,2,4-thiadiazine fusionnee et de 1,4-thiazine fusionnee, leur preparation et utilisation
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
CA2294830A1 (fr) 1997-07-16 1999-01-28 John Bondo Hansen Derives de 1,2,4-thiadiazine fusionnee, leur preparation et utilisation
CN1332943C (zh) 1998-07-08 2007-08-22 萨诺费－阿文蒂斯德国有限公司 硫取代的磺酰基氨基羧酸n－芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
US6538023B1 (en) * 2000-09-15 2003-03-25 Tsuyoshi Ohnishi Therapeutic uses of green tea polyphenols for sickle cell disease
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US20050267032A1 (en) * 2004-05-21 2005-12-01 Icagen, Inc. Sulfone-containing prodrugs
CA2615426A1 (fr) * 2005-07-18 2007-01-25 Bayer Healthcare Ag Nouvelle utilisation d'activateurs et de stimulateurs de la guanylate cyclase soluble permettant de prevenir ou de traiter des troubles renaux
MX2009011387A (es) * 2007-05-12 2009-11-09 Bayer Schering Pharma Ag Estimulantes de la gcs, activadores de la gcs y combinaciones para el tratamiento de trastornos urologicos.
DE102007026392A1 (de) * 2007-06-06 2008-12-11 Bayer Healthcare Ag Lösungen für die Perfusion und Konservierung von Organen und Geweben
EP2197551B1 (fr) 2007-09-06 2016-12-28 Merck Sharp & Dohme Corp. Activateurs de la guanylate cyclase soluble
WO2009068652A1 (fr) 2007-11-30 2009-06-04 Smithkline Beecham Corporation Pyridines 2, 6-disubstituées et pyrimidines 2, 4-disubstituées en tant qu'activateurs de guanylate cyclase soluble
WO2009071504A1 (fr) 2007-12-03 2009-06-11 Smithkline Beecham Corporation Pyridines 2,6-disubstituées comme activateurs de la guanylate cyclase soluble
EP2264017A4 (fr) 2008-04-04 2011-07-27 Takeda Pharmaceutical Dérivé hétérocyclique et son utilisation
WO2010014447A2 (fr) * 2008-07-29 2010-02-04 University Of Maryland, Baltimore Dispositif d'embolectomie pour avc
WO2010065275A1 (fr) 2008-11-25 2010-06-10 Merck Sharp & Dohme Corp. Activateurs de guanylate cyclase soluble
MX2011007515A (es) * 2009-01-17 2011-08-12 Bayer Schering Pharma Ag Estimuladores de la sgc o activadores de la sgc en combinacion con inhibidores de la pde5 para el tratamiento de la disfuncion erectil.
EP2421519B1 (fr) * 2009-04-23 2016-11-02 Universität Zürich Bloqueurs de récepteur nmda pour le traitement d'une drépanocytose
US20130035340A1 (en) * 2010-02-05 2013-02-07 Bayer Intellectual Property Gmbh sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011727A1 (fr) * 2003-08-01 2005-02-10 Pfizer Limited Combinaison d'un activateur de cyclase de guanylate soluble et d'un inhibiteur d'ace utile dans le traitement d'un trouble cardio-vasculaire ou metabolique
WO2007039155A2 (fr) * 2005-10-06 2007-04-12 Bayer Healthcare Ag Utilisation d'activateurs de la cyclase de guanylate destinee a traiter des maladies pulmonaires aigues et chroniques
WO2010144477A2 (fr) * 2009-06-12 2010-12-16 Auspex Pharmaceuticals, Inc. Modulateurs sulfonylurée du récepteur de l'endothéline
WO2011115804A1 (fr) * 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Stimulateurs de sgc

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2011161099A1 *

Also Published As

Publication number Publication date
WO2011161099A1 (fr) 2011-12-29
EP2687210A1 (fr) 2014-01-22
US20130158028A1 (en) 2013-06-20
CA2803688A1 (fr) 2011-12-29

Similar Documents

Publication Publication Date Title
EP2585055A1 (fr) Utilisation de stimulateurs et d'activateurs de la guanylate-cyclase soluble pour le traitement de la drépanocytose et la conservation de substituts sanguins
EP2822951B1 (fr) Azabicyles substitués et leur utilisation
EP2590987B1 (fr) Dérivés de 4-aminopyrimidine condensées et leur utilisation en tant que stimulateurs de la guanylate cyclase soluble
EP2576547B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
EP2802580B1 (fr) Dérivés de la triazine substituée et leur utilisation en tant que stimulateurs de la guanylate cyclase soluble
EP2705037B1 (fr) Imidazopyridazines substituées et imidazopyridazines, et leur utilisation
EP2729476B1 (fr) Pyrazolopyridines hétéroaryl substituées et leur utilisation en tant que stimulateurs de la guanylate cyclase soluble
EP2961755B1 (fr) Pyrimidines annelées à subsitution trifluorométhyle et utilisation correspondante
EP2635576B1 (fr) Carbamates substitués par des benzyles et leur utilisation
EP2961754B1 (fr) Pyrazolopyridines à substitution benzyle et leur utilisation
DE102012200349A1 (de) Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
DE102009004245A1 (de) Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
EP3325013B1 (fr) Stimulateurs / activateurs de guanylate cyclase soluble en combinaison avec un inhibiteur de l'endopeptidase neutrale (nep) et/ou un antagonist d'angiotensin ii et son utilisation
EP2705038A1 (fr) Imidazopyridazines substituées et leur utilisation
EP2874993A1 (fr) Acides aminoindano- et aminotétralinocarboxyliques substitués et leur utilisation
EP3227286B1 (fr) Pyrazolo[1,5-a]pyridines et imidazo[1,2-a]pyrazines substituées et leur utilisation
DE102010031667A1 (de) Substituierte Methyl-pyrimidin-5-ylcarbamate und ihre Verwendung
WO2012010577A1 (fr) Oxazolidinones et oxazinanones substituées et leur utilisation
DE102010031666A1 (de) Carbamat-substituierte Diaminopyrimidine und ihre Verwendung
DE102011075399A1 (de) Substituierte Imidazopyridine und Imidazopyridazine und ihre Verwendung
DE102011007891A1 (de) Annellierte 4-Aminopyrimidine und ihre Verwendung
DE102011007890A1 (de) Fluoralkyl-substituierte Pyrazolopyridine und ihre Verwendung
DE102011082041A1 (de) Substituierte annellierte Pyrimidine und ihre Verwendung
DE102010031148A1 (de) Annellierte 4-Aminopyrimidine und ihre Verwendung
DE102011078715A1 (de) Heteroaryl-substituierte Pyrazolopyridine und ihre Verwendung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130125

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

17Q First examination report despatched

Effective date: 20131220

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ADVERIO PHARMA GMBH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190326